| 000 | 01877 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250515003907.0 | ||
| 264 | 0 | _c20051108 | |
| 008 | 200511s 0 0 eng d | ||
| 022 | _a1474-547X | ||
| 024 | 7 |
_a10.1016/S0140-6736(05)67490-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKullberg, B J | |
| 245 | 0 | 0 |
_aVoriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. _h[electronic resource] |
| 260 |
_bLancet (London, England) _c |
||
| 300 |
_a1435-42 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAPACHE |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAmphotericin B _xadverse effects |
| 650 | 0 | 4 |
_aAntifungal Agents _xadverse effects |
| 650 | 0 | 4 |
_aCandidiasis _xclassification |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluconazole _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPyrimidines _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTriazoles _xadverse effects |
| 650 | 0 | 4 | _aVoriconazole |
| 700 | 1 | _aSobel, J D | |
| 700 | 1 | _aRuhnke, M | |
| 700 | 1 | _aPappas, P G | |
| 700 | 1 | _aViscoli, C | |
| 700 | 1 | _aRex, J H | |
| 700 | 1 | _aCleary, J D | |
| 700 | 1 | _aRubinstein, E | |
| 700 | 1 | _aChurch, L W P | |
| 700 | 1 | _aBrown, J M | |
| 700 | 1 | _aSchlamm, H T | |
| 700 | 1 | _aOborska, I T | |
| 700 | 1 | _aHilton, F | |
| 700 | 1 | _aHodges, M R | |
| 773 | 0 |
_tLancet (London, England) _gvol. 366 _gno. 9495 _gp. 1435-42 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(05)67490-9 _zAvailable from publisher's website |
| 999 |
_c15870798 _d15870798 |
||